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Darbepoetin alfa (Aranesp
s, Amgen) is a novel erythropoiesis-stimulating protein with a serum half-life longer than recombinant
human erythropoietin (Epo), used in the treatment of cancer-associated anaemia. Anaemia is known to adversely affect prognosis
and response to treatment in cancer patients. Solid tumours contain regions of hypoxia due to poor vascular supply and cellular
compaction. Although hypoxic stress usually results in cell death, hypoxia-resistant tumour cells are genetically unstable and often
acquire a drug-resistant phenotype. Increasing tumour oxygenation and perfusion during treatment could have the doubly beneficial
outcome of reducing the fraction of treatment-resistant cells, while increasing drug delivery to previously hypoxic tissue. In this study,
we examined the effect of darbepoetin alfa on chemotherapy sensitivity and delivery in an in vivo model of Lewis lung carcinoma,
shown here to express the Epo receptor (EpoR). We identified that weekly darbepoetin alfa treatment, commencing 10 days before
chemotherapy, resulted in a significant reduction in tumour volume compared to chemotherapy alone. This was mediated by the
prevention of anaemia, a reduction in tumour hypoxia and a concomitant increase in drug delivery. Darbepoetin alfa treatment alone
did not modulate the growth of the EpoR-expressing tumour cells. This study identifies an important role for darbepoetin alfa in
increasing the therapeutic index of chemotherapy.
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Erythropoietin (Epo) is a 30.4kDa glycoprotein hormone that
is synthesised and secreted primarily by interstitial kidney cells
in response to a hypoxic stimulus or low oxygen (O2) tension
(Krantz, 1991; Maxwell et al, 1993). Erythropoietin plays a vital
role in the regulation of erythropoiesis, and is responsible for the
maturation of Epo receptor (EpoR)-expressing erythroid progeni-
tor cells in the bone marrow that are converted to red blood cell
precursors, and subsequently to erythrocytes (Jelkmann, 1992; Lin
et al, 1996). Darbepoetin alfa or darbepoetin (Aranesp
s, Amgen)
is a unique erythropoietic molecule that differs from recombinant
human Epo (rHuEpo) in that it has two additional sialic acid-
containing carbohydrate chains, meaning that it has a longer half-
life than rHuEpo in circulation, thus requiring less-frequent dosing
(Egrie and Browne, 2001).
Anaemia is a frequent clinical manifestation in the cancer
patient, and may be caused by the tumour burden itself,
chemotherapy drugs such as cisplatin, blood loss or diminished
response to Epo (Skillings et al, 1993; Erslev, 2000). Although the
reversal of anaemia in the cancer patient is a desirable objective,
the use of Epo in this context has recently been questioned by
the discovery of the EpoR on tumour cells (Westenfelder and
Baranowski, 2000; Acs et al, 2001; Arcasoy et al, 2003) and on
endothelial cells (Anagnostou et al, 1994), leading to fears that
some tumours use Epo as a growth factor, or that it may promote
angiogenesis (Lappin et al, 2002). Two separate clinical trials were
designed to investigate the effects of epoetin alfa (Leyland-Jones,
2003) and beta (Henke et al, 2003) on cancer patients, and were
terminated prematurely due to impaired disease control. However,
substantial differences were found retrospectively in the epoetin
alfa trial between the treatment groups, such as advanced age and
lower performance status in the Epo group, which undoubtedly
complicated the interpretation of the study results (Leyland-Jones,
2003). Moreover, in the epoetin beta trial (Henke et al, 2003), the
dosing regimen raised haemoglobin levels beyond that which is
recommended in normal clinical practice (414gdl
 1 in women
and 415gdl
 1 in men). Nevertheless, these results have led to
controversy surrounding the role of Epo in an oncology setting.
Regions of hypoxia are a hallmark of solid tumours, meaning
that O2 delivery to the respiring cancer cells is reduced or
abolished as a result of excessive tumour cell proliferation in a
confined space and an inefficient vascular structure (Dachs and
Tozer, 2000; Vaupel et al, 2001). A number of factors associated
either directly or indirectly with tumour hypoxia contribute to an
overall decrease in the efficacy of chemotherapeutic agents
(reviewed by Teicher et al, 1981; Shannon et al, 2003). For
example, hypoxia causes cells to cycle more slowly (Amellem and
Pettersen, 1991), rendering them less sensitive to cytotoxic drugs
that preferentially kill rapidly proliferating cells. DNA-damaging
chemotherapeutic agents such as platinum (Pt) compounds may
have compromised function due to the increased activity of DNA
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srepair enzymes under hypoxic conditions (Walker et al, 1994), and
hypoxia also implies poor tissue permeability which affects drug
delivery and distribution (Durand, 1989).
Degner and Sutherland (1988) showed that increasing blood
haemoglobin concentration has a strong influence on hypoxic
tissue volume. As we have discussed, the chemotherapy response
of some tumours is dependent on the oxygenation status of the
tumour tissue, and attempts have been made to increase low
haemoglobin concentrations, thereby improving tissue oxygena-
tion. By these standards, rHuEpo has been shown to improve
tumour chemosensitivity by increasing haemoglobin concentra-
tion in various animal studies (Silver and Piver, 1999; Thews et al,
2001; Sigounas et al, 2004). The effects of darbepoetin in this
context have thus far not been investigated, although it has
recently been proven to be successful in increasing the therapeutic
index of radiotherapy in a murine tumour model (Ning et al,
2005). Darbepoetin is known to have greater biological activity
than rHuEpo, despite its lower affinity for the EpoR, and produces
a faster rate of haemoglobin increase (Egrie and Browne, 2001;
Egrie et al, 2003; Elliott et al, 2003). It is possible that this may
improve response to treatment, as the longer-acting darbepoetin
has been shown to result in superior responses in the prevention
of chemotherapy/radiotherapy-induced anaemia, than rHuEpo
(Hartley et al, 2003).
The chemotherapy regimen used in this study was adapted from
a 12-day metronomic cisplatin and gemcitabine dosing schedule,
shown to have a synergistic effect in the murine Lewis lung
carcinoma (LLC) model (van Moorsel et al, 1999). Data suggest
that cisplatin might share synergism with gemcitabine, possibly
due to the multiple mechanistic interactions of the two drugs; for
example, gemcitabine increases tumour Pt retention and Pt-DNA
adduct levels (van Moorsel et al, 2000). This synergism was shown
to be schedule-dependent. Recent clinical trial results indicate that
gemcitabine/Pt combinations result in significant improvements in
progression-free survival and overall survival in non-small-cell
lung cancer (NSCLC) patients compared with other Pt-based
regimens, with toxicity advantages in the cisplatin/gemcitabine
combination (Natale, 2004).
This study was designed to build further on the success of
metronomic chemotherapy scheduling by testing the hypothesis
that darbepoetin treatment, while reducing anaemia, decreases
tumour hypoxia and improves chemotherapeutic efficacy in a
murine model of LLC.
MATERIALS AND METHODS
Cell culture
The murine LLC cell line was purchased from the ATCC and
maintained in Dulbecco’s modified Eagle medium (DMEM;
GibcoBRL, UK) supplemented with 10% heat-inactivated FCS,
100IUml
 1 penicillin and 100mgml
 1 streptomycin (complete
medium). The K562 human chronic myelogenous leukaemia cell
line was obtained from the ATCC and maintained in complete
Roswell Park Memorial Institute (RPMI) 1640 medium (GibcoBRL).
All cell lines were maintained at 371C in a humidified atmosphere
containing 5% CO2. For darbepoetin stimulation, LLC cells
were growth factor deprived for 5h by incubating in serum-free
DMEM, then stimulated with 250ngml
 1 darbepoetin for 20min
or left untreated as a control.
In vivo study
Female 8–10-week-old C57BL/6 mice (Harlan Laboratories, UK)
were used. Animals were housed in a licensed biomedical facility
and had ad libitum access to animal chow and water. All
procedures were subjected to institutional ethics review and
carried out under animal licence guidelines of the Department
of Health, Ireland, and according to the UKCCCR ‘Guidelines for
the Welfare of Animals in Experimental Neoplasia’ (Workman
et al, 1998). Tumours were established by subcutaneous injection
of 1 10
6 LLC cells in 200mlC a
þ/Mg
þ-free PBS Dulbecco’s
medium (GibcoBRL) into the flank of the mice. Tumour volumes
were determined by measuring the tumour width and length twice
weekly (volume¼0.52 (width)
2 length).
Scheduling of treatments
Chemotherapy treatment was initiated 8 days after tumour
implantation, when the tumour volume was approximately 100–
150mm
3. Day 0 was defined as the first day of intraperitoneal (i.p.)
injection of chemotherapy or sterile saline (0.9% sodium chloride)
injection. All drugs were administered as 100ml i.p. injections;
chemotherapy drugs were diluted in saline, and darbepoetin was
diluted in Ca
þ/Mg
þ-free PBS Dulbecco’s medium. Mice were
randomised into four experimental groups of five mice each, and
received the following treatment on the days outlined in Figure 1;
control (group 1) received vehicle solution; darbepoetin (group 2)
received 10mgkg
 1 darbepoetin; chemotherapy (group 3) received
3mgkg
 1 cisplatin (Faulding, UK) and 60mgkg
 1 gemcitabine
(Gemzar; Eli Lilly & Co., UK); and combination chemotherapy
and darbepoetin (group 4) received cisplatin, gemcitabine and
darbepoetin according to the schedule in Figure 1. On the first day
of chemotherapy (day 0), gemcitabine was administered 4h prior
to cisplatin.
On the final day of the study (day 12; Figure 1), mice were
anaesthetised with 5% halothane (Concord Pharmaceuticals, UK)
using 5lmin
 1 O2. Blood samples were collected from mice in the
treatment groups and from normal non-tumour-bearing mice,
following a cardiac puncture. Blood was drawn up into a
disposable microcuvette, and the haemoglobin (Hb) concentration
was determined automatically using a Hemocue Hb 201
þ Analyser
(Hemocue Ltd, UK). Animals were then killed by cervical
dislocation under an anaesthetic. The study was repeated in
triplicate to provide adequate numbers of tumours for the analysis
of microvessel density, hypoxia and Pt content.
Microvessel quantification
Tumours were dissected out and flash-frozen in liquid nitrogen
and stored at –801C. Microvessel staining was carried out on 8mm
frozen sections cut through the mid-section of the tumour, which
were air-dried for 30min. Sections were fixed in cold acetone
(BDH Chemicals, UK), 1:1 acetone chloroform and acetone for
5min each, and washed in PBS. Endogenous peroxidase activity
Darbepoetin
alfa
10 g kg−1
Gem       60 mg kg−1
After 4 h:
Cis         3 mg kg
−1
Gem
Cis
Day −10 −3 Day 0 4 6 7 10
LLC
implantation
Darbepoetin Darbepoetin
Gem Gem
Sacrifice
12 11 3 −8
Figure 1 In vivo study schedule showing LLC implantation in C57 mice,
darbepoetin treatment and metronomic dosing schedule of cisplatin (Cis)
and gemcitabine (Gem).
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swas quenched by applying 3% hydrogen peroxide in methanol
(BDH) for 10min, and excess background was blocked using a
solution of 5% normal horse serum and 1% normal goat serum
(DAKO) for 20min. Sections were incubated overnight at 41C with
1mgml
 1 anti-MECA32 (rat anti-mouse panendothelial antigen
(Pharmingen, CA, USA)) diluted in blocking solution. Sections
were washed in PBS, incubated in blocking solution for 10min,
then incubated with 4mgml
 1 horseradish peroxidase (HRP)-
conjugated goat anti-rat IgG (Jackson ImmunoResearch Labora-
tories, PA, USA) diluted in blocking solution for 90min at room
temperature (RT). Sections were washed in PBS and antibody
complexes were visualised using 3,30diaminobenzidine tetra-
hydrochloride (DAB; NEN Technologies, MA, USA) for 5min
and counterstained with haematoxylin (Sigma). The sections were
then washed with distilled water and mounted with Universal
Mount (Research Genetics, AL, USA).
Hypoxia quantification
Hypoxyprobet-1 (Chemicon Europe Ltd, UK), or pimonidazole
hydrochloride, is a compound which binds only to cells with a low
O2 tension (Peters et al, 2004). On the final day of the study (day
12; Figure 1), animals were injected with 60mgkg
 1 Hypoxy-
probet-1 diluted in H2O for injection. After 90min, animals were
killed as before, and tumours were dissected out and stored in
formalin for 24h prior to paraffin embedding. Bound Hypoxy-
probet-1 adducts are then measured in 4mm formalin-fixed,
paraffin-embedded sections cut through the midsection of the
tumour, using a Hypoxyprobet-1-specific mouse monoclonal
antibody. The Animal Research Kit (ARKt, Dako) was used to
visualise the antibody binding to murine tissue, as it reduces
background binding to endogenous murine immunoglobulins.
After section rehydration through xylene (BDH) and a graded
series of alcohols to water, the sections were washed with PBS
containing 0.2% Brij 35 (Sigma) and endogenous peroxidase was
quenched using a 3% solution of hydrogen peroxide in methanol
for 10min. The sections were incubated with 0.01% pronase
(Sigma) for 30min at 371C, and rinsed in PBS-Brij. The primary
antibody (Hypoxyprobet-1 antibody: 1:50 dilution, immuno-
globulin (Ig) concentration 70mgml
 1) was incubated with the
appropriate volume of biotinylated F(ab0) anti-mouse Ig (ARKt),
then with normal mouse serum Ig (ARKt) to block anti-mouse Ig
activity. The tumour sections were incubated with the antibody
complex for 15min and rinsed in a buffer bath. Sections were
incubated with HRP-conjugated streptavidin complex (ARKt) and
antibody complexes were visualised as before.
Evaluation of staining
Tumour sections from at least five tumours per treatment group
were examined in a blinded manner under high-power magnifica-
tion ( 200) using a Nikon Eclipse E600 light microscope, and
images captured using Spot Advancedt software (Micron Optical
Co. Ltd, Ireland). For angiogenesis quantification, vessels were
counted in tumour sections and the number of vessels per mm
3 of
tumour tissue was calculated. For the quantitative analysis of
hypoxia, image analysis, carried out using Lucia Measurement on
DS Video Version 4.82 software, determined the amount of stained
hypoxic tissue (Hypoxyprobet-1-positive) as a percentage of total
area. Areas of necrotic tissue were omitted and 10 fields of view per
tumour section were analysed.
Tumour Pt determination
A relationship between Pt-DNA adduct levels and antitumour
response to cisplatin in cultured cells (Terheggen et al, 1990) and
in patient tissue (Parker et al, 1991; Schellens et al, 1996) has been
demonstrated. Platinum content in the tumours was therefore
measured as an indication of tumour drug/cisplatin delivery.
Tumours (entire) that had been flash frozen in liquid nitrogen on
day 12 (Figure 1) were weighed and digested by heating in freshly
prepared Aqua Regia (HNO3 (3)HCl) (BDH) and made up to a
known volume. A blank control was also prepared and analysed
with the samples. Inductively coupled plasma mass spectrometry
(ICP-MS) was carried out to quantify Pt using an Agilent 7500a
ICP-MS (Centre for Microscopy and Analysis, Trinity College,
Dublin, Ireland). Inductively coupled plasma mass spectrometry
atomises and ionises elements in a sample and the isotopes of the
elements are identified by their mass-to-charge ratio. The intensity
of the specific (Pt) peak in the mass spectrum is proportional to
the concentration of Pt in the original sample. The Pt concentra-
tion and original weight of the tumours were used to identify the
total amount of Pt in each tumour.
Proliferation assays
Lewis lung carcinoma cells were seeded in complete medium at a
concentration of 5 10
3well
 1 in 96-well plates and allowed to
adhere overnight at 371C in a humidified atmosphere containing
5% CO2. Medium was aspirated and medium containing 1% FCS
alone for controls, or containing cisplatin, gemcitabine or
darbepoetin at incremental concentrations, was then added to
wells in triplicate, and the incubation was continued for 48h in an
aerobic or hypoxic (1% O2) incubator (Series II CO2 Incubator,
ThermaForma, OH, USA). At this time, 40ml of a 3-[4,5
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT;
Sigma) solution (0.25mgml
 1 in PBS) was added directly to the
media. Cells were incubated at 371C for 1h, culture media was
aspirated and 100ml DMSO was added to each well to solubilise the
purple MTT reduction product formed in viable proliferating cells.
The optical density at 570nm was recorded and the proliferation
of treated cells was expressed comparatively as a percentage of
untreated controls (100%). All experiments were performed in
triplicate.
EpoR Western immunoblotting
Lewis lung carcinoma cells were washed three times in cold PBS
and lysis buffer (50mM Tris-HCl, pH 7.4, 150mM NaCl, 5mM
EDTA, 0.5% Triton-X 100, 0.5% SDS, 0.5% deoxycholic acid, 1mM
PMSF; Sigma-Aldrich, UK) was added for 1h on ice. The cells were
sheared using a syringe, and lysates cleared by centrifugation at
10000g for 30min at 41C. Murine anaemic spleens were used as
a positive control for the EpoR. Briefly, anaemia was induced in
mice using a 5mgml
 1 solution of phenylhydrazine (Sigma) in
PBS administered once a day for 2 days at 25mgkg
 1 bodyweight.
Blood haemoglobin was determined 2 days later as described
previously. Spleens from mice with a haemoglobin concentration
o10gdl
 1 were flash-frozen in liquid nitrogen, lysed, briefly
homogenised (Ultra-Turrax T8; IKA Labortechnik, Germany), and
the lysates cleared as described previously. Total protein
concentration in the lysates was determined using the bicincho-
ninic acid assay according to the manufacturer’s instructions
(Pierce, IL, USA). Equal amounts of protein were separated by 9%
SDS–PAGE and transferred to nitrocellulose membranes.
Membranes were probed using an adaptation of a previously
described method (Westenfelder et al, 1999). Briefly, blocking was
carried out with 5% non-fat dry milk in Tris-buffered saline (TBS)
containing 0.1% Tween-20 (TBST) for 2h at RT. Membranes were
probed for 1h RT with 0.27mgml
 1 (1:750) goat anti-murine
EpoR antibody (Santa Cruz Biotechnology, CA, USA). Membranes
were washed with TBST, and incubated for 90min with 0.5mgml
 1
HRP-conjugated goat anti-rabbit antibody (Dako, UK). Mem-
branes were washed in TBST and antibody complexes
were detected using enhanced chemiluminescence (Pierce, IL,
USA).
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The principal transcription factors activated by Epo are STAT5a
and STAT5b (Damen et al, 1995; Sawyer and Penta, 1996; Barber
et al, 2001). To detect transcription factor phosphorylation,
cellular lysates were obtained from LLC cells (control and
darbepoetin-stimulated). K562 lysates were used as a positive
control (de Groot et al, 1999). Equal amounts of protein were
separated by 9% SDS–PAGE and transferred to nitrocellulose
membranes. Blocking was carried out with 4% BSA (Sigma) in
TBST containing 50mM NaF (Sigma) for 2h at RT. Membranes
were probed overnight at 41C with 0.67mgml
 1 (1:300 dilution)
goat anti-human pSTAT5 antibody (Santa Cruz Biotechnology).
Membranes were washed with TBST, and incubated for 1.5h
with 0.05mgml
 1 HRP-conjugated rabbit anti-goat antibody (Dako,
UK) and antibody complexes visualised as before.
The membranes that had been probed for pSTAT5 were stripped
and re-probed with an antibody that recognises total STAT5
(STAT5a and STAT5b). Blocking was carried out with 5% non-fat
dry milk in TBST overnight at 41C. Membranes were probed for
1h RT with 1mgml
 1 (1:600 dilution) rabbit anti-murine STAT5
antibody (Santa Cruz Biotechnology). Membranes were washed
with TBST, incubated for 1.5h with 0.3mgml
 1 HRP-conjugated
goat anti-rabbit antibody (Dako, UK) and antibody complexes
visualised as before.
Statistical analysis
Statistical comparison between more than two groups was carried
out by analysis of variance (ANOVA) with LSD post hoc correction,
and between two groups by an independent-sample t-test, using
the SPSSt statistical software package (SPSS Inc., IL, USA). Data
were expressed as mean7standard error of the mean (s.e.m.) and
taken as significant where Po0.05.
RESULTS
Darbepoetin modulates chemotherapy antitumour efficacy
The administration of darbepoetin alone to tumour-bearing
animals had no effect on tumour growth compared to controls
(Figure 2A). Treatment with cisplatin and gemcitabine resulted in
a significant decrease in tumour volume compared to controls
from day 7, but, when chemotherapy and darbepoetin were
combined, there was a further significant reduction in tumour
volume compared with that seen in mice treated with chemo-
therapy alone (Po0.05) on days 10 and 12 (Figure 2B).
When darbepoetin was administered on the same day as
chemotherapy, or 3 days before, no significant difference in
tumour volume was observed (data not shown). The increase in
treatment outcome was achieved only when weekly darbepoetin
treatment at a concentration of 10mgkg
 1 was initiated 10 days
prior to the commencement of chemotherapy.
Darbepoetin prevents chemotherapy-induced anaemia
Mice with a blood haemoglobin concentration of less than 10gdl
 1
were considered anaemic. Haemoglobin values for non-tumour-
bearing mice were 13.2570.55gdl
 1 (Figure 3). Tumour-bearing
mice had an average blood haemoglobin concentration of
12.270.45gdl
 1 (nonanaemic) when untreated, and
13.0670.29gdl
 1 when treated with darbepoetin only. There was
no significant difference in haemoglobin concentration between
any of these groups. The chemotherapy regimen significantly
reduced haemoglobin to anaemic levels (9.170.39gdl
 1 Hb)
(Po0.05). Weekly darbepoetin treatment beginning 10 days before
chemotherapy prevented anaemia (12.170.34gdl
 1 Hb), thus
maintaining haemoglobin at a ‘normal’ concentration. Darbepoetin
treatment at lower doses and beginning on the same day as
chemotherapy, or 3 days before, did not result in the correction of
chemotherapy-induced anaemia (data not shown).
Darbepoetin has no effect on tumour angiogenesis
The extent of vascularisation in tumour tissue from animals in the
treatment groups was measured by the immunohistochemical
detection of panendothelial (MECA32) antigen (Figure 4). Statis-
tical analysis showed that darbepoetin treatment did not influence
tumour microvessel formation.
Darbepoetin reduces anaemia-induced tumour hypoxia
Hypoxyprobet-1 staining showed that tumours from nonanaemic
mice in the control and darbepoetin-treated groups contained
hypoxic regions of between 4.3 and 5.4% of total tumour area
(Figure 5). Darbepoetin treatment alone increased haemoglobin by
B1gdl
 1; therefore, we did not expect a significant decrease in
hypoxia in the darbepoetin-treated tumours. The chemotherapy-
treated tumours from anaemic mice contained significantly higher
levels of Hypoxyprobet-1 staining (1171.7% of tumour area) and,
therefore, the lowest level of oxygenation (Po0.05). However,
when darbepoetin treatment began 10 days before chemotherapy,
preventing anaemia, there was a significant reduction in the
percentage of hypoxic tissue to 370.4% of total tumour area,
compared to tumours treated with chemotherapy alone.
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Figure 2 (A) Tumour growth curves for mice bearing flank tumours
derived from LLC cells from the four treatment groups. Tumour volume is
expressed relative to that determined on day 0 (100%). The average
maximum tumour diameter on day 12 was 16mm. Chemotherapy groups
(* and $) Po0.05 vs control; combination chemotherapy and darbepoetin
($) Po0.05 vs chemotherapy alone (*). Statistical analysis was performed
by one-way ANOVA with LSD post hoc correction. Data are expressed as
mean7s.e.m. (B) Photograph of representative tumours derived from LLC
cells removed from chemotherapy and combination chemotherapy and
darbepoetin-treated mice after the mice were killed on day 12 using
cervical dislocation under anaesthetic. (i) Tumour from a mouse treated
with chemotherapy only; (ii) tumour from a mouse treated with
combination chemotherapy and darbepoetin.
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Total Pt levels in the tumours were measured using ICP-MS as an
indication of tumour cisplatin concentration. Tumours in the
combination chemotherapy and darbepoetin-treated group con-
tained significantly higher amounts (Po0.05) of Pt than tumours
in the group treated with chemotherapy only (Figure 6).
Chemotherapy efficacy is increased under aerobic
conditions
The cytotoxic effects of cisplatin (Figure 7A) and gemcitabine
(Figure 7B) were assessed in vitro under both aerobic and hypoxic
growth conditions to demonstrate the sensitivity of cells to
chemotherapy under different environmental conditions. Both
cisplatin and gemcitabine reduced tumour cell proliferation to
30–40% of controls under aerobic conditions (Po0.05). Under
hypoxic conditions, tumour cell proliferation was reduced;
however, the treatment of cells with either chemotherapy had no
further effect on hypoxic cells.
Lewis lung carcinoma cells express the EpoR
Lewis lung carcinoma cells were examined for EpoR protein
expression by Western blot analysis, using a murine anaemic
spleen as a positive control, as anaemia stimulates the accumula-
tion of EpoR-expressing erythroid progenitor cells in the spleen
(Youssoufian et al, 1993). There was specific binding of the
antibody directed against the murine EpoR to a 72kDa band on
LLC cells and by anaemic spleen cells (Figure 8).
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Figure 3 Blood haemoglobin concentration in the treatment groups, and in normal non-tumour-bearing mice. A blood sample was taken by carrying out
a cardiac puncture while mice were anaesthetised. Blood was collected in a microcuvette, and haemoglobin measured using an automatic Hemocue
Analyser. *Po0.05 vs other groups (note that Hbo10gdl
 1 is indicative of anaemia). Data are expressed as mean7s.e.m.
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Figure 4 Tumour microvessel density, quantified by counting vessels stained with MECA32 panendothelial antigen. The data represent the number of
microvessels per mm
3 tumour area in the treatment groups (7s.e.m.).
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To investigate whether the EpoR on LLC cells was functional, we
determined the effect of in vitro darbepoetin treatment on tumour
cell proliferation using the MTT assay. Given reports showing that
Epo may be used as a survival factor by some cells under hypoxic
conditions (Sinor and Greenberg, 2000), we carried out the
experiment under both aerobic and hypoxic (1% O2) conditions.
The results show that hypoxic conditions significantly reduced
cellular proliferation compared to aerobic controls (Figure 9).
Treatment with darbepoetin did not influence the proliferation
rate of the EpoR-expressing tumour cells under either aerobic or
hypoxic growth conditions, indicating that the receptor may be
nonfunctional on these cells.
Darbepoetin does not induce phosphorylation of STAT5 in
LLC cells
To further investigate the functionality of the EpoR, we looked
at phosphorylation of STAT5. STAT5 phosphorylation does not
occur in response to darbepoetin treatment in LLC cells
(Figure 10). The antibody used in this study has previously been
demonstrated to bind phosphorylated tyrosine of STAT5a of
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Figure 5 (A) Hypoxic tumour tissue, quantified by calculating Hypoxyprobet-1 staining as a percentage of total tumour area. The data represent the
mean percentage positive staining in the treatment groups (7s.e.m.). *Po0.05 vs other groups. (B) Representative micrographs ( 100 magnification) are
shown of Hypoxyprobet-1 binding (brown staining) in (i) a chemotherapy-treated tumour and (ii) tumour treated with combination chemotherapy and
darbepoetin.
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Figure 6 Tumour Pt content, measured using ICP-MS, in chemotherapy-
treated tumours compared with tumours in the combination chemother-
apy and darbepoetin group. Data are expressed as the mean7s.e.m. and
statistical analysis was performed by an independent sample t-test.
*Po0.05 vs chemotherapy only.
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smurine origin (Goleva et al, 2002). Blots were subsequently
stripped and probed using an antibody that recognises total STAT5
to verify equal loading of samples. STAT5 consists of STAT5a
(94kDa) and STAT5b (96kDa), and therefore appears as a double
band.
DISCUSSION
This study provides evidence that weekly darbepoetin supplemen-
tation indirectly increases the therapeutic index of a metronomic
cisplatin and gemcitabine chemotherapy schedule in a murine
model of LLC. The observed increase in treatment outcome was
dependent on the prevention of anaemia, which resulted in
decreased tumour hypoxia. The hypothesis that Epo treatment to
maintain a normal haematocrit enhances chemotherapy anti-
tumour efficacy has previously been investigated. Increased cisplatin-
induced tumour regression was found in combination with
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Figure 7 The cytotoxic effects of chemotherapies on tumour cell
proliferation. Lewis lung carcinoma cells were cultured in the presence of
cisplatin (A) and gemcitabine (B) and viability was assessed after 48h
under aerobic or hypoxic (1% O2) growth conditions using the MTT assay.
Data are expressed as a percentage of untreated control cell proliferation
under aerobic growth conditions (% means7s.e.m.). Data represent 3
independent 48h MTT experiments. *Po0.05 vs normoxic control.
EpoR →
Anaemic LLC
spleen cells
Figure 8 Lewis lung carcinoma cells were cultured under normal growth
conditions and proteins were isolated from the cell line and from lysed
murine anaemic spleens. Following separation of proteins by SDS–PAGE,
proteins were transferred to a nitrocellulose membrane and probed with
anti-EpoR antibody. EpoR expression was analysed by X-ray autoradio-
graphy. Data represent typical results of one of three independent
experiments.
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Figure 9 Lewis lung carcinoma cells were cultured in the presence of
darbepoetin (10–1000ngml
 1) under aerobic or hypoxic (1% O2) growth
conditions, and proliferation was assessed after 48h using the MTT assay.
Hypoxic conditions significantly reduce LLC cell proliferation (*Po0.05 vs
normoxic control). Data are expressed as a percentage of aerobic control
(% means7s.e.m.) and represent three independent MTT experiments.
Statistical analysis was performed by one-way ANOVA with LSD post hoc
correction.
pSTAT5 →
K562 LLC LLC cells +
cells cells darbepoetin
 STAT5 →
Figure 10 Lewis lung carcinoma cells were serum-starved for 5h and
then stimulated for 20min with darbepoetin alfa (250ngml
 1), or left
untreated as a control. K562 cells, in which STAT5 is constitutively
phosphorylated, were used as a positive control. After treatment, the cells
were washed and lysed. Following separation of proteins by SDS–PAGE,
blots were probed with anti-phospho-specific STAT5 antibody and
pSTAT5 expression was analysed by X-ray autoradiography. Data
represent typical results of one of three independent experiments. The
membrane was stripped and probed with an antibody that recognises total
STAT5 (bottom).
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srHuEpo treatment (Silver and Piver, 1999). Another group
artificially induced anaemia by carboplatin administration and
used rHuEpo to correct anaemia and increase drug sensitivity
(Thews et al, 2001). Sigounas et al (2004) showed, also in a LLC
murine model, that rHuEpo synergised with cisplatin to further
suppress tumour growth. However, the cisplatin regime used in
this study did not induce anaemia, so the enhancement of
treatment efficacy in this instance was not related to the prevention
of anaemia. The investigators hypothesised that the results
reflected improved oxygenation of the hypoxic tumour tissue, as
a result of the increase in O2 availability due to rHuEpo. To our
knowledge, we are the first to prove, through the measurement of
pimonidazole adducts, that darbepoetin decreases tumour hypoxia
in chemotherapy-treated tumours compared with tumours from
anaemic mice treated with chemotherapy alone. We show that,
even with a small decrease in tumour tissue hypoxia, an
improvement in outcome can be achieved, confirming the negative
impact of hypoxia on prognosis.
Ning et al (2005) recently demonstrated that the correction
of anaemia in tumour-bearing mice, by darbepoetin, increased
tumour oxygenation and subsequently sensitivity towards a 5-day
course of radiotherapy. The use of recombinant Epo proteins to
restore anaemia-induced reduction in radiosensitivity is well
documented (Thews et al, 1998; Stuben et al, 2003). Interestingly
however, this paper provides information that radiotherapy
efficacy is augmented, even in the absence of the correction of
anaemia or tumour hypoxia. The tumour cells employed in that
experiment did not express the EpoR, ruling out a direct
antitumour effect. In the present study, we provide the information
that, although LLC cells express the EpoR, darbepoetin treatment
does not stimulate proliferation of the cells or result in STAT5
phosphorylation. As the EpoR is redundant on the tumour cells,
this verifies that the correction of anaemia is the explanation for
the increased therapeutic outcome. This paper supports the
reports from long-term follow-up in darbepoetin clinical trials
that indicate no tumour-promoting or detrimental effect of
darbepoetin on survival in patients with cancer (Vansteenkiste
et al, 2002; Hedenus et al, 2003).
Darbepoetin did not affect the number of tumour microvessels
in our model, but, as it served to reduce tumour hypoxia in
chemotherapy-treated tumours, downregulation of hypoxia-indu-
cible vascular endothelial growth factor (VEGF) expression and
vascular permeability could occur (Shweiki et al, 1992; Dvorak
et al, 1999). Permeable tumour vessels in a disorganised
vasculature lead to interstitial fluid pressure, impairing drug
delivery to tumours (Netti et al, 1999). Darbepoetin could
therefore function to maintain normal vasculature integrity,
explaining the increased Pt content in the combination darbepoe-
tin and chemotherapy-treated tumours, compared to tumours
treated with chemotherapy alone.
Cisplatin (Koch et al, 2003) and gemcitabine (Yokoi and Fidler,
2004) have previously been shown to have greater efficacy under
normoxic, compared to hypoxic growth, conditions, a result also
reported in the present paper. Preventing tumour hypoxia using
darbepoetin not only increases the sensitivity of tumour cells to
chemotherapy as the therapeutic index of most drugs is augmented
under normoxic conditions, but also has the added benefit of
slowing down the process of hypoxia-associated malignant
progression. Moreover, the correction of anaemia and its
associated symptoms, particularly fatigue, improves patients’
quality of life. This may have implications for improving tolerance
to therapy, which may lead to more patients completing an entire
course of treatment with increased likelihood of therapeutic
response (Blackwell et al, 2004).
We conclude that darbepoetin improves therapeutic outcome by
an indirect mechanism, which is the prevention of anaemia and a
subsequent reduction of tumour hypoxia, resulting in increased
tumour cell chemosensitivity. A direct effect of darbepoetin on
EpoR-expressing tumour cells is ruled out in this case, as the cells
were shown not to respond to the hormone. We have also shown
that darbepoetin treatment ‘normalises’ haemoglobin to control
levels (Hbo14gdl
 1), not to suprapharmacological levels. This
bodes well for clinical applications where elevated haemoglobin
levels could have a negative effect due to thrombovascular risk. It
must be noted that this is a single tumour model using a single
treatment regimen, and further investigation into the conse-
quences of darbepoetin treatment in combination with chemo-
therapy is necessary.
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